Nemolizumab (Nemluvio, Galderma) Improves Itch and Skin Lesions in AD Patients for Up to Two Years
Nemolizumab (Nemluvio, Galderma) produces sustained and increased improvements in atopic dermatitis (AD) symptoms, including itch and skin lesions, for up to two years with no new safety signals identified, according to data from a new interim analysis of a long-term extension study. These data were presented in a late-breaker abstract at the Revolutionizing Atopic Dermatitis […]